Fieke Hoff: The need for a refined risk stratification model for older patients with AML
Fieke Hoff, Clinical hematology/oncology fellow at NIH NHLBI, shared on X:
“Excited to share our publication in Blood Advances emphasizing the need for a refined risk stratification model for older patients with AML receiving lower-intensity treatment. A great collaboration with The Leukemia and Lymphoma Society.”
Authors: Fieke W. Hoff, William Blum, Ying Huang, Rina Li Welkie, Ronan Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Kellie J. Archer, Prapti A. Patel, Robert H. Collins Jr., Maria R. Baer, Vu H. Duong, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca L. Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily Curran, Kristin L. Koenig, Nyla A. Heerema, Timothy L. Chen, Molly Martycz, Mona Stefanos, Leonard Rosenberg, Brian J. Druker, Ross L. Levine, Amy Burd, Ashley O. Yocum, Uma Borate, Alice S. Mims, John C. Byrd, Yazan F. Madanat
Brittany Knick Ragon, Associate Professor at Levine Cancer, replied:
“It was around 8 years ago, Fieke Hoff, helped me stay sane as I navigated fellowship, a new baby (with only 5 weeks maternity leave), and a unique leukemia/MDS research effort. Nothing makes me happier than seeing her shine and her continued commitment to leukemia research! Well done!”
Source: Fieke Hoff/X and Brittany Knick Ragon/X